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Abstract
Background: Coronavirus disease 2019 (COVID-19) is caused by severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2) appears with common symptoms including fever, dry cough, and fatigue, as well as some less
common sysmptoms such as loss of taste and smell, diarrhea, skin rashes and discoloration of fingers. COVID-19
patients may also suffer from serious symptoms including shortness of breathing, chest pressure and pain, as well
as loss of daily routine habits, pointing out to a sever reduction in the quality of life. COVID-19 has afftected almost
all countries, however, the United States contains the highest number of infection (> 1,595,000 cases) and deaths
cases (> 95,000 deaths) in the world until May 21, 2020. Finding an influential treatment strategy against COVID-19
can be facilitated through better understanding of the virus pathogenesis and consequently interrupting the
biochemical pathways that the virus may play role in human body as the current reservoir of the virus.
Results: In this study, we combined system biology and bioinformatic approaches to define the role of
coexpression of angiotensin-converting enzyme 2 (ACE2), neprilysin or membrane metallo-endopeptidase (MME),
and carbonic anhydrases (CAs) and their association in the pathogenesis of SARS-CoV-2. The results revealed that
ACE2 as the cellular attachment site of SARS-CoV-2, neprilysin, and CAs have a great contribution together in the
renin angiotensin system (RAS) and consequently in pathogenesis of SARS-CoV-2 in the vital organs such as
respiratory, renal, and blood circulation systems. Any disorder in neprilysin, ACE2, and CAs can lead to increase of
CO2 concentration in blood and respiratory acidosis, induction of pulmonary edema and heart and renal failures.
Conclusions: Due to the presence of ACE2-Neprilysin-CA complex in most of vital organs and as a receptor of
COVID-19, it is expected that most organs are affected by SARS-CoV-2 such as inflammation and fibrosis of lungs,
which may conversely affect their vital functions, temporary or permanently, sometimes leading to death. Therefore,
ACE2-Neprilysin-CA complex could be the key factor of pathogenesis of SARS-CoV-2 and may provide us useful
information to find better provocative and therapeutic strategies against COVID-19.
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Background
Since the emergence of severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2) and the worldwide outbreak
of coronavirus disease 2019 (COVID-19), the number of
infected and death cases have exceeded 4,300,000 and
290,000, respectively until May 21, 2020. Taken together all
the observations, world health organization (WHO) declared
COVID-19 as a pandemic viral infection based on the preva-
lence rate and severity of the disease [1, 2] (Table 1).
The COVID-19 patients suffer from several clinical
symtoms including fever, dry cough, fatigue, headache,
sore throat, loss of taste and smell, aches and pains,
diarrhea, skin rashes and/or discoloration of fingers and
toes, shortness of breathing, chest pressure and pain,
and loss of speech and movement. Since the outbreak of
COVID-19 around the world, many academic groups
and pharmaceutical companies have focused on develop-
ing therapeutic compounds to provide an effective
vaccine against COVID-19. The studies revealed that
remdesivir [3], combination of lopinavir and ritonavir
(weak recommendation) [4], corticosteroids [5], inter-
feron along with combination of lopinavir and ritonavir
[4], and immunoglobulin-therapy through transfusion of
immune plasma can be the possible thearapetic options
for treatment of COVID-19. For COVID-19 prevention,
the studies can focus on the results obtained from
SARS-CoV vaccine clinical trials such as application of
DNA, viral vector, subunit, viral-like particle, inactivated
virus, and live-attenuated virus platforms [6].
To achieve an effective treatment, it is necessary to know
more about the mechanism of action and pathogenesis of
SARS-CoV-2. Four structural proteins including spike (S),
membrane (M), nucleocapsid (N), and envelope (E) anti-
gens are the main constituents of SARS-CoV-2 [7]. S pro-
tein is a 150 kDa glycoprotein with a N-terminal signal
peptide sequence, which is glycosylated at endoplasmic
reticulum (ER) [8]. The most abundant structural protein is
M protein (25–30 kDa) comprising three transmembrane
domains with crucial roles in the virion formation and sta-
bilizing the complexes during the virion assembly through
binding of a small glycosylated N-terminal region of M pro-
tein to N protein [9]. N protein (50–60 kDa) binds to RNA
through N-terminal domain (NTD) and C-terminal domain
(CTD), which is induced by phosphorylation of N protein,
genomic packaging signal (GPS), replicase-transcriptase
complex (RTC), and transcription regulatory signal (TRS)
Table 1 Statistics of worldwide COVID-19 cases until May 21, 2020
Continent Country (top 3 countries
for confirmed cases)
Confirmed cases Deaths Recovered cases
Asia Iran > 129,000 > 7250 > 100,560
India > 113,300 > 3450 > 45,900
China > 82,960 > 4600 > 78,200
Europe Russia > 317,500 > 3100 > 92,600
Spain > 279,500 > 27,900 > 197,000
UK > 248,300 > 35,700 N/A
North America United States > 1,595,000 > 95,000 > 371,000
Canada > 80,100 > 6000 > 40,800
Mexico > 56,600 > 6100 > 38,900
South America Brazil > 294,100 > 19,000 > 117,000
Peru > 104,000 > 3000 > 42,000
Chile > 53,600 > 544 > 22,500
Africa South Africa > 18,000 > 340 > 9000
Egypt > 14,200 > 680 > 4000
Morocco > 7200 > 200 > 4200
Oceania Australia > 7100 > 100 > 6500
New Zealand > 1500 > 20 > 1450
French Polynesia > 60 0 > 60
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[10]. E protein (8–12 kDa) is a transmembrane protein with
ion channel activity and a major role in assembly and
release of virions from the infected cells [11]. Although E
protein is not required for replication of the virus, it it plays
role in pathogenesis of SARS-CoVs.
At the cellular level, the first viral entry step is the binding
of the viral trimeric S protein to the human angiotensin con-
verting enzyme 2 (ACE2) receptor [12]. Moreover, CD147
[13], dendritic cell-specific intercellular adhesion molecule-3-
grabbing non-integrin (DC-SIGN, CD209) [14] and L-SIGN
(CD209L) [15] are other entry receptors for SARS-CoV-2.
ACE2 is a glycosylated zinc metallopeptidase and a part of
the local renin-angiotensin system (RAS). Based on native
function of type I membranous endopeptidases in modifica-
tion of N-terminal region of proteins, ACE2 contains an
extracellular N-terminal active site [16]. This enzyme is
expressed in most tissues including kidneys, heart, intestine
and lungs, and hydrolyse circulating angiotensisn molecules.
ACE2 counteracts the effects of ACE by converting
angiotensin I into Ang-(1-7) and reducing the amount
of angiotensin II and balancing the ratio of circulating
Ang II/ Ang-(1-7) levels [17, 18]. Elevated Ang II pro-
duction in the pulmonary system triggers local vascular
permeability which may result in lung edema [19, 20].
Moreover, Ang II induces pulmonary vasoconstriction in
response to hypoxia. Ang-(1-7) has vasodilator, anti-
proliferative, and anti-angiogenic properties, while Ang II is a
vasoconstrictor, a mitogenic, and an angiogenic factor [21].
In acute respiratory distress syndrome (ARDS), if the
RAS does not help in oxygenation, the general lung
injury will result in pulmonary failure. Most probably, in
ARDS models, ACE2 knockout will result in more severe
symptoms, while overexpression might protect the lung
from further injury [22].
As mentioned, ACE2 is also exploited by SARS-CoV-2
as the entry receptor. Due to the high expression of ACE2
in the lungs, intestines, respiratory tract, and also enteric
system, these organs are the main sites of SARS-CoV-2 in-
fections that are manifested by symptoms like fever, cough,
pneumonia, shortness or difficulty of breathing, anorexia,
sometimes diarrhea, and abdominal pain [23]. Therefore, it
is considered that coronavirus infection can be controlled
by blocking ACE2 and preventing the virus from binding
to the cells [12]. Despite the mentioned assumption, some
animal studies have shown that an increase in Ang-(1-7)
has a protective effect against virus-induced lung injury via
the vasodilatory effects [22, 24]. It seems that, persistent
angiotensin II activity may be partly responsible for organ
injury in COVID-19 [19].
Due to insufficient information on the infectious
mechanism of the virus, most studies have focused on
preventing the first stage of viral infection by reducing
ACE2, but ACE2 knock down leads to high activation of
local RAS and increased tissue injury, hypertension and
renal and cardiovascular complications. Therefore, the
evaluation of the efficacy of recently designed vaccines
for COVID-19 requires appropriate animal models such
as ACE2-transgenic and ACE2-knockout mice [25].
Although, ACE2 is the major producer of Ang-(1-7),
there are other enzymes such as neprilysin, prolyl-endo-
peptidase (PEP) and prolyl-carboxy-peptidase (PCP) that
can produce Ang-(1-7) from Ang I [26, 27]. Among the
aforementioned enzymes, high expression levels of neprily-
sin have been detected in the lung, especially in pulmonary
epithelial cells [21]. This zinc-dependent MME is expressed
in a wide variety of tissues and in addition to hydrolyzing
the Ang I to Ang-(1-7), it is involved in converting several
endogenous propeptides into their functional form.
According to evidence, neprilysin regulates lung tissue re-
sponses to broncho-constriction inducing peptides [21, 28].
Thus, upregulation of neprilysin can be considered as a
compensatory mechanism to control the concentration of
Ang-(1-7) levels during COVID-19 treatment.
Airway management and hyperbaric oxygen therapy
(HBOT) is the main supportive treatments for patients
with severe COVID-19 as well as severe pneumonia [29].
Previous studies have revealed that the levels of both
angiotensinogen and Ang II receptors increases in
hypoxic conditions [30, 31]. Consequently, hypoxic con-
ditions in COVID-19 will increase Ang II concentration
through downregulation of ACE2 [32, 33]. Lungs and
alveoli as the main parts of lower respiratory system
have the main role in the oxygen (O2) exchange with
carbon dioxide (CO2) at the molecular level; CA plays a
crucial function in this respiratory exchange [34, 35]. CA
as another Zn-metalloenzyme catalyzes the hydration of
CO2 into carbonic acid and vice versa [36–38]. One of
the adaptive responses to hypoxia includes the increased
expression and functional activation of CA IX [39]. In this
study, we applied a system biology approach to explore
the association of ACE2, neprilysin, and CA, which may
ameliorate COVID-19 symptoms in the lungs alveoli.
Methods
Identification of Coexpression of ACE2, Neprilysin, and CA
To identify role of coexpression of ACE2, neprilysin, and
CA in COVID-19 pathogenesis, we used COXPRESdb
v7 (https://coxpresdb.jp/) [40]. In this database, we ap-
plied the CoexViwer algorithm to identify and draw the
coexpression of genes, which are linked to activation of
neprilysin. This database facilitates the visualization of
the multiple gene coexpression information derived from
defined animals which were examined with a variety of
transcriptomics technologies.
Identification of the Association of Neprilysin and ACE2
To identify the association of neprilysin and ACE2, we
employed KEGG (Kyoto Encyclopedia of Genes and
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Genomes) PATHWAY database [41]. This database rep-
resents the information on the reactions, relation net-
works, and molecular interactions of the molecules.
Identification of Organ Localization of ACE2, Neprilysin,
and CA
To identify the organ localization of ACE2, neprilysin, and
CA, we used THE HUMAN PROTEIN ATLAS online pro-
gram (https://www.proteinatlas.org/) [42]. This program
shows the map of the localization of human proteins in
cells, organs, and tissues through application of various sys-
tem biology, proteomics, and transcriptomics technologies.
Results
Identification of Coexpression of ACE2, Neprilysin, and CA
The coexpression study revealed that ACE2, neprilysin,
and CA are codominantly expressed in the local RAS.
The analysis showed that at least 22 genes were coex-
pressed in the local RAS, which can be linked to
COVID-19. This association can be a direct or an indir-
ect coexpression effect; so lack of function of a protein
as the consequence of COVID-19 infection may induce
the expression or activity of another protein in a differ-
ent pathway (Fig. 1) (Table 2).
Identification of Association of Neprilysin and ACE2
The KEGG PATHWAY defined that neprilysin and
ACE2 have association in the RAS. In this system, via
two individual biochemical procedures, neprilysin con-
verts Ang I and Ang-(1-9) to Ang-(1-7). In addition, in
the RAS, ACE2 facilitates three individual biochemical
procedures including conversion of Ang l to Ang-(1-9)
as the substrate of neprilysin, Ang II to Ang-(1-7), and
Ang A to alamandine which binds to Mas-related G
Fig. 1 Coexpression of ACE2, neprilysin or MME, and CA in RAS. Red arrows are showing ACE2-Neprilysin-CA association network. The network
consist of 22 proteins that two out of them are still not characterized
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protein-coupled receptor (MrgprD) to perform the vaso-
dilatory action (Fig. 2).
Identification of Organ Localization of ACE2, Neprilysin,
and CA
Our analysis based on the data obtained from THE HU-
MAN PROTEIN ATLAS revealed that neprilysin and
ACE2 are highly expressed in the digestive, renal, respira-
tory, and reproductive systems. The expression pattern of
CA in the atlas has shown that this protein is expressed in
all human organs. These overlaps in the organ localization
of ACE2, neprilysin, and CA demonstrate the possible
association of these proteins as a complex in COVID-19
infections through overexpression or down regulation of
coding genes expression (Fig. 3).
Discussion
The successful computational methodologies were
employed previously to design viral vaccines against in-
fluenza A, hepatitis A, HIV-1, dengue, and West Nile
viruses so a new era was considered in the vaccine
Table 2 Genes directly connected with neprilysin on the
coexpression network
Locus Function Entrez Gene ID
CA VB carbonic anhydrase 5B 302,669
ACE2 angiotensin-converting enzyme 2 302,668
Fig. 2 Association of neprilysin or MME and ACE2. ACE2 is crucial in conversion of angiotensin I to Ang-(1-9) angiotsnsin II to Ang-(1-7), and
angiotensin A (AngA) to alamandine. In addition, neprilysin or MME is essential in conversion of angiotensin I to Ang-(1-7) and Ang-(1-9) to
angiotensin Ang-(1-7)
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design studies, which was named reverse vaccinology
2.0 [43–45]. This approach was designed and imple-
mented to demonstrate the importance of combination
of human immunology, clinical biochemistry, microbial
genomics, and system biology to establish novel multi-
disciplinary approaches in the pathogenesis studies of
pathogens and vaccinology researches [45, 46].
The bioinformatics analysis reveals the moderate coex-
pression of ACE2, neprilysin, and CA genes in the
human body. As soon as SARS-CoV-2 is entered into
the human oral cavity via direct contact or sneezing and
cough droplets of a COVID-19 patient, the virus S
protein can be attached to the ACE2, the main host cell
receptor of SARS-CoV-2 expressed by epithelial cells of
Fig. 3 Localization of (a) neprilysin or MME, (b) ACE2, and (c) CA VB in the human organs. THE HUMAN PROTEIN ATLAS shows the overlap of
bars and association of ACE2, neprilysin, and CA in various organs including digestive, renal, respiratory, and reproductive systems
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different sites of the oral cavity [47, 48]. Single-cell
transcriptome study revealed that the expression rate of
ACE2 in the tongue tissue is higher than buccal and
gingival tissues [49]. Therefore, primarily SARS-CoV-2
multiplicities in the human mucosa of the oral cavity
and consequently a high number of viruses are transmit-
ted to the secondary organ targets expressing ACE2. For
this reason, some have claimed drinking water could be
a safe way against SARS-CoV-2 which wash the virus
into the stomach where acid will inactivate it.
Single-cell sequencing (scRNA-Seq) has shown a high
expression rate for ACE2 in type II alveolar (AT2) cells
of lung [50], oral cavity epithelial cells [51], upper
esophagus [14] and cholangiocytes [52]. A reduction in
ACE2 levels due to internalizing by attached SARS-
CoV-2 leads to increase in Ang II and consequently
vasoconstriction in the lung [53]. Such condition causes
respiratory disorders and insufficient air conditioning
in alveoli which stimulates lung to upregulate ACE2 ex-
pression [54]. According to bioinformatics predictionof
the coexpression of ACE2, neprilysin, and CA; an increase
in neprilysin and upregulation of CA may attenuate the
severity of disease and compensate the alveolar ventilation
[55–59]. The elevated Ang II in lung tissue following a
decrease in ACE2 by COVID-19 binding may increase the
comorbidities, most likely due to inducing local and
systemic inflammation. The proinflammatory effects of
Ang II are mediated by increased oxidative stress. Elevated
serum concentrations of C-reactive protein (CRP) is an in-
dicator of systemic inflammation in such conditions [60].
ACE2 also is expressed in other tissues including prox-
imal tubular cells of kidney [61], colon and ileum of the
digestive system [62], urothelial cells of the gallbladder
[49], and liver, pancreas and heart myocytes [63], which
can justify COVID-19 infection side effects. ACE2 is also
expressed in lymphocytes and following infection with
the virus, their population decreases and the immune
system weakens [13].
Also, different isoenzymes of CA have a high rate of
expression in various tissues with critical biochemical
functions in the pH homeostasis and alveolar O2-CO2
exchange [64]. After the inhalation, the oxygen is entered
to alveoli of lungs with higher pressure than blood capil-
laries and delivered to hemoglobin in red blood cells
(RBCs) [65]. Then, H2CO3 is catalyzed to CO2 and water
molecule by CA ll of RBCs. In the acute COVID-19,
following the destructive effects of virus on the pulmonary
cells, the O2-CO2 exchange rate is impaired, leading to
respiratory acidosis and shifting the pH of blood to acidic
state and also increasing the concentration of blood CO2
[66]. Subsequently, the kidney proximal tubular cells
increase reabsorption of HCO3
− leading to acid and am-
monium excretion [67]. Then, H+ of the tubular fluid is
combined with HCO3
− producing H2CO3, which is
catalyzed to H2O and CO2 by CAs localized in kidney tis-
sue [68]. Hence, as the consequence of infection of various
cells including pulmonary cells of lungs, myocytes of
heart, proximal tubular cells of kidney, and other ACE2-
expressing cells (which mainly express CAs) with SARS-
CoV-2 and reducing the ability of CO2 exhalation, the
concentration of blood CO2 is elevated so even the lungs
alveoli became unable in O2-CO2 exchange with pulmon-
ary artery and vein through the CA enzymatic reaction
[69]. The respiratory acidosis is associated with weakness
of the respiratory muscles, arrhythmias, hypotension,
myocardial depression, and decreasing in renal blood flow
[66]. As the immunological aspect, the respiratory acidosis
induces apoptosis and release of proinflammatory cyto-
kines following RAS activation and raising the expression
level of angiotensinogen by leukocytes [70]. Finally, the
respiratory acidosis can lead to pulmonary edema, severe
hypoxia as well as heart and renal failures [66]. Regarding
to coexpression analyses results and referring to lack of
sufficient information related to human CA VB, we
couldn’t find the reason of the coexpression prediction of
neprilysin and ACE2 with CA VB, which needs further ex-
periments in future.
Conclusions
Overally, due to high expression rate of ACE2 in the human
organs and presence of a potential association with neprily-
sin in RAS and CAs, SARS-CoV-2 could be considered as
an aggressive pathogen to all human organs which express
ACE2. Therefore, this pathologic association (ACE2-Nepri-
lysin-CA) complex can present valuable physiologic infor-
mation to clinicians to innovate more influential treatment
protocols against COVID-19.
Abbreviations
ACE2: Angiotensin-converting enzyme 2; ARDS: Acute respiratory distress
syndrome; HCO3
−: Bicarbonate; H2CO3: Carbonic acid; CA: Carbonic
anhydrase; COVID-19: Coronavirus disease 2019; CO2: Carbon dioxide; CRP: C-
reactive protein; DC-SIGN: Dendritic cell-specific intercellular adhesion
molecule-3-grabbing non-integrin; E: Envelope; HBOT: Hyperbaric oxygen
therapy; HIV: Human immunodeficiency virus; KEGG: Kyoto Encyclopedia of
Genes and Genomes; M: Membrane; MME: Membrane metallo-
endopeptidase; MrgprD: Mas-related G protein-coupled receptor;
N: Nucleocapsid; O2: Oxygen; RAS: Renin angiotensin system; RBC: Red blood
cell; S: Spike; SARS-CoV-2: Severe acute respiratory syndrome coronavirus 2
Acknowledgements
We thank the Deputy of Research and COVID-19 National Committee at the
National Institute of Genetic Engineering and Biotechnology (NIGEB) of the
Islamic Republic of Iran for preparing the condition to perform this study. No
funding organizations had any role in the design of the study; in the
collection, analyses, or interpretation of data; in the writing of the
manuscript; nor in the decision to publish the results.
Authors’ Contributions
All authors participated in the design of the study. RZE designed and carried
out the search and data mining related to the coexpression of ACE2-
Neprilysin-CA complex as well as databases for this study. RZE performed the
system biology and bioinformatic studies. RF participated in the
immunological and EB participated in the biochemical studies and further
Zolfaghari Emameh et al. Biological Procedures Online           (2020) 22:11 Page 7 of 9
revision of the manuscript. All authors participated in writing further versions
and read and approved the final manuscript.
Funding
To perform this study, RZE received a research grant support from the
National Institute of Genetic Engineering and Biotechnology (NIGEB) of the
Islamic Republic of Iran.
Availability of Data and Materials
All data analyzed in this study were prepared from online databases, which
were included in this article.
Ethics Approval and Consent to Participate
Not applicable.
Consent for Publication
All authors have read and approved the final version of the manuscript.
Competing Interests
The authors declare that they have no conflict of interests.
Author details
1Department of Energy and Environmental Biotechnology, National Institute
of Genetic Engineering and Biotechnology (NIGEB), 14965/161, Tehran, Iran.
2Immunology Research Center, Iran University of Medical Sciences, Tehran,
Iran. 3Department of Biochemistry, Faculty of Medicine, Iran University of
Medical Sciences, Tehran, Iran.
Received: 20 April 2020 Accepted: 1 June 2020
References
1. Mahase E. Covid-19: WHO declares pandemic because of “alarming levels”
of spread, severity, and inaction. BMJ. 2020;368:m1036.
2. Zolfaghari Emameh R, Nosrati H, Taheri RA. Combination of biodata mining
and computational modelling in identification and characterization of
ORF1ab polyprotein of SARS-CoV-2 isolated from Oronasopharynx of an
Iranian patient. Biol Proced Online. 2020;22:8.
3. Grein J, Ohmagari N, Shin D, Diaz G, Asperges E, Castagna A, et al.
Compassionate use of Remdesivir for patients with severe Covid-19. N Engl
J Med. 2020;NEJMoa2007016.
4. Jin YH, Cai L, Cheng ZS, Cheng H, Deng T, Fan YP, et al. A rapid advice
guideline for the diagnosis and treatment of 2019 novel coronavirus (2019-
nCoV) infected pneumonia (standard version). Mil Med Res. 2020;7(1):4.
5. Russell CD, Millar JE, Baillie JK. Clinical evidence does not support
corticosteroid treatment for 2019-nCoV lung injury. Lancet. 2020;
395(10223):473–5.
6. Prompetchara E, Ketloy C, Palaga T. Immune responses in COVID-19 and
potential vaccines: lessons learned from SARS and MERS epidemic. Asian
Pac J Allergy Immunol. 2020;38(1):1–9.
7. McBride R, van Zyl M, Fielding BC. The coronavirus nucleocapsid is a
multifunctional protein. Viruses. 2014;6(8):2991–3018.
8. Belouzard S, Millet JK, Licitra BN, Whittaker GR. Mechanisms of coronavirus
cell entry mediated by the viral spike protein. Viruses. 2012;4(6):1011–33.
9. Arndt AL, Larson BJ, Hogue BG. A conserved domain in the coronavirus
membrane protein tail is important for virus assembly. J Virol. 2010;84(21):
11418–28.
10. Zuniga S, Cruz JL, Sola I, Mateos-Gomez PA, Palacio L, Enjuanes L.
Coronavirus nucleocapsid protein facilitates template switching and is
required for efficient transcription. J Virol. 2010;84(4):2169–75.
11. Verdia-Baguena C, Nieto-Torres JL, Alcaraz A, DeDiego ML, Torres J, Aguilella
VM, et al. Coronavirus E protein forms ion channels with functionally and
structurally-involved membrane lipids. Virology. 2012;432(2):485–94.
12. Yan R, Zhang Y, Li Y, Xia L, Guo Y, Zhou Q. Structural basis for the
recognition of SARS-CoV-2 by full-length human ACE2. Science. 2020;
367(6485):1444–8.
13. Wang X, Xu W, Hu G, Xia S, Sun Z, Liu Z, et al. SARS-CoV-2 infects T
lymphocytes through its spike protein-mediated membrane fusion. Cell Mol
Immunol. 2020:1–3.
14. Qi F, Qian S, Zhang S, Zhang Z. Single cell RNA sequencing of 13 human
tissues identify cell types and receptors of human coronaviruses. Biochem
Biophys Res Commun. 2020;526(1):135–40.
15. Jeffers SA, Tusell SM, Gillim-Ross L, Hemmila EM, Achenbach JE, Babcock GJ,
et al. CD209L (L-SIGN) is a receptor for severe acute respiratory syndrome
coronavirus. Proc Natl Acad Sci U S A. 2004;101(44):15748–53.
16. Varland S, Osberg C, Arnesen T. N-terminal modifications of cellular proteins:
the enzymes involved, their substrate specificities and biological effects.
Proteomics. 2015;15(14):2385–401.
17. Paul M, Poyan Mehr A, Kreutz R. Physiology of local renin-angiotensin
systems. Physiol Rev. 2006;86(3):747–803.
18. Gandhi C, Uhal BD. Roles of the angiotensin system in neonatal lung injury
and disease. JSM Atheroscler. 2016;1(3):1014.
19. Deng J, Wang DX, Deng W, Li CY, Tong J. The effect of endogenous
angiotensin II on alveolar fluid clearance in rats with acute lung injury. Can
Respir J. 2012;19(5):311–8.
20. Imai Y, Kuba K, Penninger JM. The renin-angiotensin system in acute
respiratory distress syndrome. Drug Discov Today Dis Mech. 2006;3(2):225–9.
21. Gallagher PE, Cook K, Soto-Pantoja D, Menon J, Tallant EA. Angiotensin
peptides and lung cancer. Curr Cancer Drug Targets. 2011;11(4):394–404.
22. Imai Y, Kuba K, Penninger JM. The discovery of angiotensin-converting
enzyme 2 and its role in acute lung injury in mice. Exp Physiol. 2008;
93(5):543–8.
23. Adhikari SP, Meng S, Wu YJ, Mao YP, Ye RX, Wang QZ, et al. Epidemiology,
causes, clinical manifestation and diagnosis, prevention and control of
coronavirus disease (COVID-19) during the early outbreak period: a scoping
review. Infect Dis Poverty. 2020;9(1):29.
24. Jia H. Pulmonary angiotensin-converting enzyme 2 (ACE2) and
inflammatory lung disease. Shock (Augusta, Ga). 2016;46(3):239–48.
25. Imai Y, Kuba K, Rao S, Huan Y, Guo F, Guan B, et al. Angiotensin-
converting enzyme 2 protects from severe acute lung failure. Nature.
2005;436(7047):112–6.
26. Grobe N, Weir NM, Leiva O, Ong FS, Bernstein KE, Schmaier AH, et al.
Identification of prolyl carboxypeptidase as an alternative enzyme for
processing of renal angiotensin II using mass spectrometry. Am J Phys Cell
Phys. 2013;304(10):C945–53.
27. Domenig O, Manzel A, Grobe N, Konigshausen E, Kaltenecker CC, Kovarik JJ,
et al. Neprilysin is a mediator of alternative renin-angiotensin-system
activation in the murine and human kidney. Sci Rep. 2016;6:33678.
28. Wick MJ, Buesing EJ, Wehling CA, Loomis ZL, Cool CD, Zamora MR,
et al. Decreased neprilysin and pulmonary vascular remodeling in
chronic obstructive pulmonary disease. Am J Respir Crit Care Med.
2011;183(3):330–40.
29. Geier MR, Geier DA. Respiratory conditions in coronavirus disease 2019
(COVID-19): important considerations regarding novel treatment strategies
to reduce mortality. Med Hypotheses. 2020;140:109760.
30. Hubloue I, Rondelet B, Kerbaul F, Biarent D, Milani GM, Staroukine M, et al.
Endogenous angiotensin II in the regulation of hypoxic pulmonary
vasoconstriction in anaesthetized dogs. Crit Care. 2004;8(4):R163–71.
31. Zhao L. al-Tubuly R, Sebkhi a, Owji AA, Nunez DJ, Wilkins MR. angiotensin II
receptor expression and inhibition in the chronically hypoxic rat lung. Br J
Pharmacol. 1996;119(6):1217–22.
32. Mohamed TL, Nguyen HT, Abdul-Hafez A, Dang VX, Dang MT, Gewolb IH,
et al. Prior hypoxia prevents downregulation of ACE-2 by hyperoxia in fetal
human lung fibroblasts. Exp Lung Res. 2016;42(3):121–30.
33. Varagic J, Ahmad S, Nagata S, Ferrario CM. ACE2: angiotensin II/angiotensin-
(1-7) balance in cardiac and renal injury. Curr Hypertens Rep. 2014;16(3):420.
34. Farhi LE, Plewes JL, Olszowka AJ. Lung carbonate dehydratase
(carbonic anhydrase), CO2 stores and CO2 transport. CIBA Found
Symp. 1976;38:235–49.
35. Klocke RA. Catalysis of CO2 reactions by lung carbonic anhydrase. J Appl
Physiol Respir Environ Exerc Physiol. 1978;44(6):882–8.
36. Zolfaghari Emameh R, Barker HR, Syrjanen L, Urbanski L, Supuran CT, Parkkila
S. Identification and inhibition of carbonic anhydrases from nematodes. J
Enzyme Inhib Med Chem. 2016;31(sup4):176–84.
37. Zolfaghari Emameh R, Kuuslahti M, Vullo D, Barker HR, Supuran CT, Parkkila
S. Ascaris lumbricoides beta carbonic anhydrase: a potential target enzyme
for treatment of ascariasis. Parasit Vectors. 2015;8:479.
38. Zolfaghari Emameh R, Kuuslahti M, Nosrati H, Lohi H, Parkkila S. Assessment
of databases to determine the validity of beta- and gamma-carbonic
anhydrase sequences from vertebrates. BMC Genomics. 2020;21(1):352.
Zolfaghari Emameh et al. Biological Procedures Online           (2020) 22:11 Page 8 of 9
39. Pastorekova S, Gillies RJ. The role of carbonic anhydrase IX in cancer
development: links to hypoxia, acidosis, and beyond. Cancer Metastasis Rev. 2019;
38(1-2):65–77.
40. Obayashi T, Kagaya Y, Aoki Y, Tadaka S, Kinoshita K. COXPRESdb v7: a gene
coexpression database for 11 animal species supported by 23 coexpression
platforms for technical evaluation and evolutionary inference. Nucleic Acids
Res. 2019;47(D1):D55–62.
41. Du J, Yuan Z, Ma Z, Song J, Xie X, Chen Y. KEGG-PATH: Kyoto encyclopedia
of genes and genomes-based pathway analysis using a PATH analysis
model. Mol BioSyst. 2014;10(9):2441–7.
42. Thul PJ, Lindskog C. The human protein atlas: a spatial map of the human
proteome. Protein Sci. 2018;27(1):233–44.
43. Khan AM, Hu Y, Miotto O, Thevasagayam NM, Sukumaran R, Abd Raman HS,
et al. Analysis of viral diversity for vaccine target discovery. BMC Med Genet.
2017;10(Suppl 4):78.
44. Hasan M, Ghosh PP, Azim KF, Mukta S, Abir RA, Nahar J, et al. Reverse
vaccinology approach to design a novel multi-epitope subunit vaccine
against avian influenza a (H7N9) virus. Microb Pathog. 2019;130:19–37.
45. Rappuoli R, Bottomley MJ, D'Oro U, Finco O, De Gregorio E. Reverse
vaccinology 2.0: human immunology instructs vaccine antigen design. J Exp
Med. 2016;213(4):469–81.
46. Zolfaghari Emameh R, Kuuslahti M, Nareaho A, Sukura A, Parkkila S.
Innovative molecular diagnosis of Trichinella species based on beta-
carbonic anhydrase genomic sequence. Microb Biotechnol. 2016;9(2):172–9.
47. Hoffmann M, Kleine-Weber H, Schroeder S, Kruger N, Herrler T, Erichsen S,
et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked
by a clinically proven protease inhibitor. Cell. 2020;181(2):271.
48. Lan J, Ge J, Yu J, Shan S, Zhou H, Fan S, et al. Structure of the SARS-CoV-2
spike receptor-binding domain bound to the ACE2 receptor. Nature. 2020;
581(7807):215.
49. Xu H, Zhong L, Deng J, Peng J, Dan H, Zeng X, et al. High expression of
ACE2 receptor of 2019-nCoV on the epithelial cells of oral mucosa. Int J Oral
Sci. 2020;12(1):8.
50. Uhal BD, Dang M, Dang V, Llatos R, Cano E, Abdul-Hafez A, et al. Cell cycle
dependence of ACE-2 explains downregulation in idiopathic pulmonary
fibrosis. Eur Respir J. 2013;42(1):198–210.
51. de Carvalho Fraga CA, Farias LC, Jones KM. Batista de Paula AM, Guimaraes
ALS. Angiotensin-converting enzymes (ACE and ACE2) as potential targets for
malignant epithelial neoplasia: review and bioinformatics analyses focused in
Oral squamous cell carcinoma. Protein Pept Lett. 2017;24(9):784–92.
52. Zhang C, Shi L, Wang FS. Liver injury in COVID-19: management and
challenges. Lancet Gastroenterol Hepatol. 2020;5(5):428.
53. South AM, Tomlinson L, Edmonston D, Hiremath S, Sparks MA.
Controversies of renin-angiotensin system inhibition during the COVID-19
pandemic. Nat Rev Nephrol. 2020;16(6):305.
54. Li G, He X, Zhang L, Ran Q, Wang J, Xiong A, et al. Assessing ACE2
expression patterns in lung tissues in the pathogenesis of COVID-19. J
Autoimmun. 2020;1:102463.
55. Sparks MA, Crowley SD, Gurley SB, Mirotsou M, Coffman TM. Classical renin-
angiotensin system in kidney physiology. Compr Physiol. 2014;4(3):1201–28.
56. Ahmad S, Varagic J, Groban L, Dell’Italia LJ, Nagata S, Kon ND, et al.
Angiotensin-(1-12): a chymase-mediated cellular angiotensin II substrate.
Curr Hypertens Rep. 2014;16(5):429.
57. Park S. Ideal target blood pressure in hypertension. Korean Circ J. 2019;
49(11):1002–9.
58. Simoni J, Simoni G, Moeller JF, Tsikouris JP, Wesson DE. Evaluation of
angiotensin converting enzyme (ACE)-like activity of acellular hemoglobin.
Artif Cells Blood Substit Immobil Biotechnol. 2007;35(2):191–210.
59. Patel VB, Zhong JC, Grant MB, Oudit GY. Role of the ACE2/angiotensin 1-7
Axis of the renin-angiotensin system in heart failure. Circ Res. 2016;118(8):
1313–26.
60. Bansal T, Pandey A. D D, Asthana AK. C-reactive protein (CRP) and its
association with periodontal disease: a brief review. J Clin Diagn Res. 2014;
8(7):ZE21–4.
61. Soler MJ, Wysocki J, Batlle D. ACE2 alterations in kidney disease. Nephrol
Dial Transplant. 2013;28(11):2687–97.
62. Vuille-dit-Bille RN, Camargo SM, Emmenegger L, Sasse T, Kummer E, Jando J,
et al. Human intestine luminal ACE2 and amino acid transporter expression
increased by ACE-inhibitors. Amino Acids. 2015;47(4):693–705.
63. Gallagher PE, Ferrario CM, Tallant EA. Regulation of ACE2 in cardiac
myocytes and fibroblasts. Am J Physiol Heart Circ Physiol. 2008;295(6):
H2373–9.
64. Everaert N, Willemsen H, Hulikova A, Brown H, Decuypere E, Swietach
P, et al. The importance of carbonic anhydrase II in red blood cells
during exposure of chicken embryos to CO2. Respir Physiol Neurobiol.
2010;172(3):154–61.
65. Carlson BE, Anderson JC, Raymond GM, Dash RK, Bassingthwaighte JB.
Modeling oxygen and carbon dioxide transport and exchange using a
closed loop circulatory system. Adv Exp Med Biol. 2008;614:353–60.
66. Bruno CM, Valenti M. Acid-base disorders in patients with chronic
obstructive pulmonary disease: a pathophysiological review. J Biomed
Biotechnol. 2012;2012:915150.
67. DuBose TD Jr. Carbonic anhydrase-dependent bicarbonate transport in the
kidney. Ann N Y Acad Sci. 1984;429:528–37.
68. Frommer JP, Wesson DE, Laski ME, Kurtzman NA. Generation of reabsorptive
bicarbonate concentration gradients between vasa recta and papillary
tubular fluid after inhibition of carbonic anhydrase in the rat kidney. Ann N
Y Acad Sci. 1984;429:541–3.
69. Xu XW, Wu XX, Jiang XG, Xu KJ, Ying LJ, Ma CL, et al. Clinical findings in a
group of patients infected with the 2019 novel coronavirus (SARS-Cov-2)
outside of Wuhan, China: retrospective case series. BMJ. 2020;368:m606.
70. Liao Z, Chakrabarty A, Mu Y, Bhattacherjee A, Goestch M, Leclair CM, et al. A
local inflammatory renin-angiotensin system drives sensory axon sprouting
in provoked Vestibulodynia. J Pain. 2017;18(5):511–25.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Zolfaghari Emameh et al. Biological Procedures Online           (2020) 22:11 Page 9 of 9
